Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
55 | Publisher: Global Research & Data Services
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Nicotine Addiction - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Nicotine Addiction - Pipeline Review, H1 2015’, provides an overview of the Nicotine Addiction’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Nicotine Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nicotine Addiction and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Nicotine Addiction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Nicotine Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Nicotine Addiction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Nicotine Addiction Overview 7 Therapeutics Development 8 Pipeline Products for Nicotine Addiction - Overview 8 Pipeline Products for Nicotine Addiction - Comparative Analysis 9 Nicotine Addiction - Therapeutics under Development by Companies 10 Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes 11 Nicotine Addiction - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Nicotine Addiction - Products under Development by Companies 14 Nicotine Addiction - Products under Investigation by Universities/Institutes 15 Nicotine Addiction - Companies Involved in Therapeutics Development 16 AbbVie Inc. 16 Astraea Therapeutics, LLC 17 Embera NeuroTherapeutics, Inc. 18 FORUM Pharmaceuticals Inc. 19 Heptares Therapeutics Ltd. 20 Omeros Corporation 21 Nicotine Addiction - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Combination Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 29 Drug Profiles 31 (oxazepam + metyrapone) - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 AT-1001 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 encenicline hydrochloride - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 OMS-405 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 OMS-527 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SLV-330 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Vaccine for Nicotine Addiction - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Vaccine for Nicotine Addiction - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Nicotine Addiction - Recent Pipeline Updates 46 Nicotine Addiction - Dormant Projects 50 Nicotine Addiction - Discontinued Products 51 Nicotine Addiction - Product Development Milestones 52 Featured News & Press Releases 52 Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 52 May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors 52 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables Number of Products under Development for Nicotine Addiction, H1 2015 8 Number of Products under Development for Nicotine Addiction - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Nicotine Addiction - Pipeline by AbbVie Inc., H1 2015 16 Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2015 17 Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 18 Nicotine Addiction - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 19 Nicotine Addiction - Pipeline by Heptares Therapeutics Ltd., H1 2015 20 Nicotine Addiction - Pipeline by Omeros Corporation, H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Assessment by Combination Products, H1 2015 23 Number of Products by Stage and Target, H1 2015 25 Number of Products by Stage and Mechanism of Action, H1 2015 27 Number of Products by Stage and Route of Administration, H1 2015 28 Number of Products by Stage and Molecule Type, H1 2015 30 Nicotine Addiction Therapeutics - Recent Pipeline Updates, H1 2015 46 Nicotine Addiction - Dormant Projects, H1 2015 50 Nicotine Addiction - Discontinued Products, H1 2015 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
